ALEXANDRA FINGESTEN: Open Payments
NPI 1972658185 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,248 in 58 payments from 14 companies in 2025. Trend: 2023 $1,558 · 2024 $1,792 · 2025 $1,248
Food & beverage: $1,248
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $286 |
| Novo Nordisk Inc | 11 | $172 |
| Axsome Therapeutics, Inc. | 4 | $122 |
| ABBVIE INC. | 5 | $121 |
| Vanda Pharmaceuticals Inc. | 4 | $97 |
| Neurocrine BioSciences, Inc. | 4 | $91 |
| Lundbeck LLC | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 5 | $77 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
Products named: VIVITROL, REXULTI, Ozempic, Auvelity, FANAPT, INGREZZA, AUSTEDO XR, UBRELVY.
Industry payments across NY — which companies pay providers there.
